Drug discovery startup Peptris has secured Rs 70 crore ($7.7 million) in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest, among others. The new funds will enable Peptris to progress towards clinical readiness, expand its pipeline, and strengthen its teams specializing in biology, chemistry, data science, and AI.
Founded in 2019, Peptris utilizes AI models to create innovative molecules and forecast crucial drug development parameters, aiming to minimize failures in the drug discovery process. This approach has already led to the discovery of Novel Chemical Entities (NCEs) and opportunities for repurposing existing drugs.
Despite advancements in science, drug discovery remains a slow, costly, and failure-prone endeavor, leaving significant unmet medical needs. Peptris’ platform not only generates unique molecules but also forecasts vital drug development parameters early on, enabling quicker and more informed decision-making. This has resulted in the discovery of NCEs and opportunities for drug repurposing and rescue, with multiple programs progressing towards clinical development.
The Bengaluru-based startup plans to launch several new NCE programs and multiple drug repurposing initiatives. By following a business-to-business (B2B) engagement model, Peptris collaborates closely with pharmaceutical, biotech, and select FMCG partners to license assets and co-develop programs. Focused on therapeutic areas like rare diseases, inflammation, oncology, and women’s health, Peptris aims to make a lasting impact on patients, caregivers, and healthcare systems worldwide.
Source: Entrackr : Latest Posts